InvestSMART

Firebrick Pharma Limited (ASX: FRE) - Announcements

- Current share price for FRE : $0.030

ASX company news and announcements for Firebrick Pharma Limited (FRE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Firebrick Pharma Limited (FRE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Firebrick Pharma Limited (FRE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Firebrick Pharma Limited (FRE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$9 Completion of Share Purchase Plan 10 Oct 2024 8:43AM $0.055 $0.030 fallen by 45.45%
$9 Firebrick Investor Update Webinar Recording 1 Oct 2024 7:03PM $0.060 $0.030 fallen by 50%
$9 Final Director's Interest Notice - Richard Treagus 1 Oct 2024 8:18AM $0.058 $0.030 fallen by 48.28%
$9 Notice of AGM and Closing Date for Director Nominations 30 Sep 2024 8:21AM $0.060 $0.030 fallen by 50%
$9 Firebrick Investor Update 25 Sep 2024 9:32AM $0.052 $0.030 fallen by 42.31%
$9 Firebrick receives $0.9 million R&D Tax Incentive 23 Sep 2024 8:28AM $0.056 $0.030 fallen by 46.43%
$9 Share Purchase Plan Open 17 Sep 2024 11:16AM $0.053 $0.030 fallen by 43.40%
$9 Cleansing Notice Pursuant to Share Purchase Plan 17 Sep 2024 8:23AM $0.056 $0.030 fallen by 46.43%
$9 Resignation of Director Dr Richard Treagus 12 Sep 2024 9:54AM $0.059 $0.030 fallen by 49.15%
$9 Proposed issue of securities - FRE 12 Sep 2024 8:26AM $0.065 $0.030 fallen by 53.85%
$9 Share Purchase Plan 12 Sep 2024 8:21AM $0.065 $0.030 fallen by 53.85%
$9 Notification regarding unquoted securities - FRE 10 Sep 2024 1:15PM $0.065 $0.030 fallen by 53.85%
$9 Proposed issue of securities - FRE 9 Sep 2024 8:35AM $0.066 $0.030 fallen by 54.55%
$9 FRE Consultant to Drive Pharmacy Distribution in Singapore 9 Sep 2024 8:29AM $0.066 $0.030 fallen by 54.55%
$9 Nasodine European Marketing Application Filed and Validated 9 Sep 2024 8:20AM $0.066 $0.030 fallen by 54.55%
$9 Cleansing Notice 4 Sep 2024 9:44AM $0.060 $0.030 fallen by 50%
$9 Application for quotation of securities - FRE 4 Sep 2024 8:59AM $0.060 $0.030 fallen by 50%
$9 Appendix 4G 30 Aug 2024 1:02PM $0.060 $0.030 fallen by 50%
$9 Corporate Governance Statement 30 Aug 2024 1:02PM $0.060 $0.030 fallen by 50%
$9 Appendix 4E and Annual Report 30 June 2024 30 Aug 2024 1:01PM $0.060 $0.030 fallen by 50%
$9 New agreement allows Nasodine launch in Philippines 15 Aug 2024 8:18AM $0.055 $0.030 fallen by 45.45%
$9 June 2024 Quarterly Activity Report & Appendix 4C 30 Jul 2024 8:32AM $0.048 $0.030 fallen by 37.50%
$9 Change of Director's Interest Notice - Peter Molloy 28 Jun 2024 5:04PM $0.056 $0.030 fallen by 46.43%
$9 Nasodine Phase 1 Paper Published 17 Jun 2024 8:19AM $0.067 $0.030 fallen by 55.22%
$9 Firebrick Launches Nasodine in Singapore 13 Jun 2024 8:24AM $0.059 $0.030 fallen by 49.15%

151 - 175 of 510 results

Page 7 of 21

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.